A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder

World Journal of Biological Psychiatry

Volumn 3, Issue 3, 2002, Pages 150-155

  Shytle, R Douglas ^a,b   Silver, Archie A ^a,b   Wilkinson, Berney J ^b   Sanberg, Paul R ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

ADHD; attention; learning; nicotine; nicotinic

Indexed keywords

NICOTINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NICOTINE; PILOT PROJECTS;

EID: 0036632416     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970209150616     Document Type: Article

References (42)

1. Biederman J, Faraone SV, Mick E, Williamson S, Wilens TE, Spencer TJ, Weber W, jetton J, Kraus I, Pert J, Zallen B (1999) Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources. J Am Acad Child Adolesc Psychiatry 38:966-975.
2. Buccafusco JJ, Jackson WJ, Terry AV, Marsh KC, Decker MW, Arneric SP (1995) Improvement in performance of a delayed matching-tosample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology (Berl) 120:256-266.
3. Clarke PB, Fu DS, Jakubovic A, Fibiger HC (1988) Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 246:701-708.
4. Coger RW, Moe KL, Serafetinides EA (1996) Attention deficit disorder in adults and nicotine dependence: psychobiological factors in resistance to recovery? J Psychoactive Drugs 28:229-240.
5. DSM-IV (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC.
6. Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. The Journal of Pharmacology and Experimental Therapeutics 288:88-92.
7. Fung YK, Lau YS (1989) Effects of prenatal nicotine exposure on rat striatal dopaminergic and nicotinic systems. Pharmacol Biochem Behav 33:1-6.
8. Caub M, Carlson CL (1997) Gender differences in ADHD: a metaanalysis and critical review. J Am Acad Child Adolesc Psychiatry 36:1036-1045.
9. Coyette CH, Conners CK, Ulrich RF (1978) Normative data on revised Conners Parent and Teacher Rating Scales. J Abnorm Child Psychol 6:221-236.
10. Johns JM, Walters PA, Zimmerman LI (1993) The effects of chronic prenatal exposure to nicotine on the behavior of guinea pigs (Cavia porcellus). J Gen Psychol 120:49-63.
11. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485-494.
12. Kiss JP, Vizi ES, Westerink BH (1999) Effect of neostigmine on the hippocampal noradrenaline release: role of cholinergic receptors. Neuroreport 10:81-86.
13. Klein RG, Abikoff H, Barkley RA, Campbell M, Leckman JF, Ryan ND, Solanto MV (1994) Clinical Trials in Children and Adolescents. In: Prien RF, Robinson DS (eds) Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. Raven Press Ltd, New York, pp 501-546.
14. Levin ED (1992) Nicotinic systems and cognitive function. Psychopharmacology (Berl) 108:417-431.
15. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J (1996) Nicotine effects on adults with attentiondeficit/hyperactivity disorder. Psychopharmacology (Berl) 123:55-63.
16. Meck WH, Church RM (1987) Cholinergic modulation of the content of temporal memory. Behav Neurosci 101:457-464.
17. Milberger S, Biederman J, Faraone SV, Chen L, Jones J (1997) ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:37-44.
18. Newhouse PA, Potter A, Kelton M, Corwin J (2001) Nicotinic treatment of Alzheimer's disease. Biol Psychiatry 49:268-278.
19. Newman MB, Shytle RD, Sanberg PR (1999) Locomotor behavioral effects of prenatal and postnatal nicotine exposure in rat offspring. Behav Pharmacol 10:699-706.
20. NIMH (1985) Clinical Global Impression (CGI) scale. Psychopharmacol Bull 21:839-843.
21. Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A (1997) Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. Br J Pharmacol 120:429-438.
22. Parrott AC, Winder G (1989) Nicotine chewing gum (2 mg, 4 mg) and cigarette smoking: comparative effects upon vigilance and heart rate. Psychopharmacology 97:257-261.
23. Peeke SC, Peeke HV (1984) Attention, memory, and cigarette smoking. Psychopharmacology 84:205-216.
24. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS (1995) Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 7:373-378.
25. Reuben M, Boye S, Clarke PB (2000) Nicotinic receptors modulating somatodendritic and terminal dopamine release differ pharmacologically. Eur J Pharmacol 393:39-49.
26. Rose JE, Behm FM, Westman EC (1998) Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 6:331-343.
27. Sanberg PR, McConville BJ, Fogelson HM, Manderscheid PZ, Parker KW, Blythe MM, Klykylo WM, Norman AB (1989) Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed Pharmacother 43:19-23.
28. Sanberg PR, Shytle RD, Silver AA (1998) Treatment of Tourette's syndrome with mecamylamine [letter]. Lancet 352:705-706.
29. Sharp WS, Walter JM, Marsh WL, Ritchie GF, Hamburger SD, Castellanos FX (1999) ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 38:40-47.
30. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22-33; quiz 34-57.
31. Shott S (1990) Statistics for Health Professionals. Harcourt Brace Jovanovich Inc, Philadelphia, PA.
32. Shytle RD, Silver AA, Sanberg PR (2000) Comorbid bipolar disorder in tourette syndrome responds to nicotinic receptor antagonist, mecamylamine (Inversine). Biol Psychiatry 48:1028-1031.
33. Silver AA, Shytle RD, Sanberg PR (2000) Mecamylamine in Tourette's syndrome: a two-year retrospective case. J Child Adolesc Psychopharmacol 10:59-68.
34. Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR (2001a) Multi-Center Double Blind Placebo Controlled Study of Mecamylamine Monotherapy for Tourette's Disorder. J Am Acad Child Adolesc Psychiatry 40:1103-1110.
35. Silver AA, Shytle RD, Wilkinson B, McConville B, Sanberg PR (2001b) Transdermal Nicotine and Haloperidol in Tourette Syndrome: a double-blind placebo controlled study. J Clin Psychiatry 62:707-714.
36. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327.
37. Summers KL, Kern WR, Giacobini E (1997) Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Jpn J Pharmacol 74:139-146.
38. Terry AV, Buccafusco JJ, Prendergast MA (1999) Dose-specific improvements in memory-related performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine. Drug Development Research 47:127-136.
39. Wesnes K, Warburton DM (1984) The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology 82:338-342.
40. Wilens T, Biederman J, Spencer T, Bostic J, Prince J, Monuteaux BS, Soriano J, Fine C, Abrams A, Rater M (1998) A controlled trial of ABT-418 for Attention Deficit Hyperactivity Disorder in adults. Am J Psychiatry 56:1931-1937.
41. Young JM, Shytle RD, Sanberg PR, George TP (2001) Mecamylamine: new therapeutic uses and toxicity/risk profile. Clin Ther 23:532-565.
42. Zametkin AJ, Liotta W (1998) The neurobiology of attentiondeficit/ hyperactivity disorder. J Clin Psychiatry 59:17-23.